Hanna Mandel1, Shotaro Saita2, Simon Edvardson3, Chaim Jalas4, Avraham Shaag3, Dorit Goldsher5, Euvgeni Vlodavsky6, Thomas Langer2, Orly Elpeleg3. 1. Metabolic Unit, Rambam Health Care Center, Rappaport School of Medicine, Technion, Haifa, Israel. 2. Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. 3. The Monique and Jacques Roboh Department of Genetic Research, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 4. Bonei Olam, Center for Rare Jewish Genetic Disorders, Brooklyn, New York, USA. 5. MRI Unit, Rambam Medical Center, Ruth and Baruch Rappaport School of Medicine, Technion, Israel Institute of Technology, Haifa, Israel. 6. Department of Pathology, Rambam Medical Center, Ruth and Baruch Rappaport School of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Abstract
BACKGROUND: Cell survival critically depends on the integrity of mitochondria, which play a pivotal role during apoptosis. Extensive mitochondrial damage promotes release of pro-apoptotic factors from the intermembrane space of mitochondria. Released mitochondrial proteins include Smac/DIABLO and HTRA2/Omi, which inhibit the cytosolic E3 ubiquitin ligase XIAP and other inhibitors of apoptosis proteins. AIMS: Here we investigated the cause of extreme hypertonia at birth, alternating with hypotonia, with the subsequent appearance of extrapyramidal symptoms, lack of psychomotor development, microcephaly, intractable seizures and early death in four patients from two unrelated families. The patients showed lactic acidemia, 3-methylglutaconic aciduria, intermittent neutropenia, evolving brain atrophy and disturbed cristae structure in muscle mitochondria. METHODS AND RESULTS: Using whole-exome sequencing, we identified missplicing mutation and a 5 bp deletion in HTRA2, encoding HTRA2/Omi. This protein was completely absent from the patients' fibroblasts, whose growth was impaired and which were hypersensitive to apoptosis. Expression of HtrA2/Omi or of the proteolytically inactive HTRA2/Omi protein restored the cells' apoptotic resistance. However, cell growth was only restored by the proteolytically active protein. CONCLUSIONS: This is the first report of recessive deleterious mutations in HTRA2 in human. The clinical phenotype, the increased apoptotic susceptibility and the impaired cell growth recapitulate those observed in the Htra2 knockout mice and in mutant mice with proteolytically inactive HTRA2/Omi. Together, they underscore the importance of both chaperone and proteolytic activities of HTRA2/Omi for balanced apoptosis sensitivity and for brain development. Absence of HTRA2/Omi is associated with severe neurodegenerative disorder of infancy, abnormal mitochondria, 3-methylglutaconic aciduria and increased sensitivity to apoptosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Cell survival critically depends on the integrity of mitochondria, which play a pivotal role during apoptosis. Extensive mitochondrial damage promotes release of pro-apoptotic factors from the intermembrane space of mitochondria. Released mitochondrial proteins include Smac/DIABLO and HTRA2/Omi, which inhibit the cytosolic E3 ubiquitin ligase XIAP and other inhibitors of apoptosis proteins. AIMS: Here we investigated the cause of extreme hypertonia at birth, alternating with hypotonia, with the subsequent appearance of extrapyramidal symptoms, lack of psychomotor development, microcephaly, intractable seizures and early death in four patients from two unrelated families. The patients showed lactic acidemia, 3-methylglutaconic aciduria, intermittent neutropenia, evolving brain atrophy and disturbed cristae structure in muscle mitochondria. METHODS AND RESULTS: Using whole-exome sequencing, we identified missplicing mutation and a 5 bp deletion in HTRA2, encoding HTRA2/Omi. This protein was completely absent from the patients' fibroblasts, whose growth was impaired and which were hypersensitive to apoptosis. Expression of HtrA2/Omi or of the proteolytically inactive HTRA2/Omi protein restored the cells' apoptotic resistance. However, cell growth was only restored by the proteolytically active protein. CONCLUSIONS: This is the first report of recessive deleterious mutations in HTRA2 in human. The clinical phenotype, the increased apoptotic susceptibility and the impaired cell growth recapitulate those observed in the Htra2 knockout mice and in mutant mice with proteolytically inactive HTRA2/Omi. Together, they underscore the importance of both chaperone and proteolytic activities of HTRA2/Omi for balanced apoptosis sensitivity and for brain development. Absence of HTRA2/Omi is associated with severe neurodegenerative disorder of infancy, abnormal mitochondria, 3-methylglutaconic aciduria and increased sensitivity to apoptosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Patricia E Fitzsimons; Charlotte L Alston; Penelope E Bonnen; Joanne Hughes; Ellen Crushell; Michael T Geraghty; Martine Tetreault; Peter O'Reilly; Eilish Twomey; Yusra Sheikh; Richard Walsh; Hans R Waterham; Sacha Ferdinandusse; Ronald J A Wanders; Robert W Taylor; James J Pitt; Philip D Mayne Journal: Am J Med Genet A Date: 2018-03-25 Impact factor: 2.802
Authors: Kyle Thompson; Homa Majd; Cristina Dallabona; Karit Reinson; Martin S King; Charlotte L Alston; Langping He; Tiziana Lodi; Simon A Jones; Aviva Fattal-Valevski; Nitay D Fraenkel; Ann Saada; Alon Haham; Pirjo Isohanni; Roshni Vara; Inês A Barbosa; Michael A Simpson; Charu Deshpande; Sanna Puusepp; Penelope E Bonnen; Richard J Rodenburg; Anu Suomalainen; Katrin Õunap; Orly Elpeleg; Ileana Ferrero; Robert McFarland; Edmund R S Kunji; Robert W Taylor Journal: Am J Hum Genet Date: 2016-09-29 Impact factor: 11.025
Authors: Matthew Merski; Cátia Moreira; Rui Mv Abreu; Maria João Ramos; Pedro A Fernandes; L Miguel Martins; Pedro José Barbosa Pereira; Sandra Macedo-Ribeiro Journal: Cell Death Dis Date: 2017-10-12 Impact factor: 8.469
Authors: Monika Oláhová; Kyle Thompson; Steven A Hardy; Inês A Barbosa; Arnaud Besse; Maria-Eleni Anagnostou; Kathryn White; Tracey Davey; Michael A Simpson; Michael Champion; Greg Enns; Susan Schelley; Robert N Lightowlers; Zofia M A Chrzanowska-Lightowlers; Robert McFarland; Charu Deshpande; Penelope E Bonnen; Robert W Taylor Journal: J Inherit Metab Dis Date: 2016-09-30 Impact factor: 4.982